1. Home
  2. EVAX vs SCLX Comparison

EVAX vs SCLX Comparison

Compare EVAX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.25

Market Cap

29.7M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$4.96

Market Cap

35.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
SCLX
Founded
2008
2011
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.7M
35.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
EVAX
SCLX
Price
$3.25
$4.96
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $11.67
N/A
AVG Volume (30 Days)
★ 50.5K
28.1K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$122.52
Revenue Next Year
$328.20
$186.30
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.77
$4.20
52 Week High
$12.15
$29.84

Technical Indicators

Market Signals
Indicator
EVAX
SCLX
Relative Strength Index (RSI) 58.34 35.89
Support Level $2.92 $4.85
Resistance Level $3.33 $5.60
Average True Range (ATR) 0.15 0.31
MACD 0.02 0.04
Stochastic Oscillator 87.14 7.81

Price Performance

Historical Comparison
EVAX
SCLX

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: